ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
13.78
-0.86 (-5.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 28.75, with a low estimate of 27 and a high estimate of 30. The average target predicts an increase of 108.64% from the current stock price of 13.78.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 7, 2025.
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +117.71% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +103.19% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +95.94% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +117.71% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +81.42% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
90.48M
from 89.15M
Increased by 1.49%
Revenue Next Year
218.67M
from 90.48M
Increased by 141.68%
EPS This Year
-1.38
from 0.08
EPS Next Year
-0.57
from -1.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 135.4M | 318.7M | 444.2M | ||
| Avg | 90.5M | 218.7M | 344.9M | ||
| Low | 54.5M | 115.3M | 190.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 51.9% | 252.3% | 103.1% | ||
| Avg | 1.5% | 141.7% | 57.7% | ||
| Low | -38.9% | 27.4% | -12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.99 | - | 0.84 | ||
| Avg | -1.38 | -0.57 | 0.24 | ||
| Low | -1.54 | -1.20 | -0.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.